{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T14:19:14Z","timestamp":1784297954885,"version":"3.55.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T00:00:00Z","timestamp":1718668800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.intimp.2024.112506","type":"journal-article","created":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T05:48:05Z","timestamp":1719208085000},"page":"112506","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Platelet-to-lymphocyte percentage ratio for assessing disease activity and predicting therapeutic outcomes in ulcerative colitis"],"prefix":"10.1016","volume":"137","author":[{"given":"Jieqi","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minhu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8230-1995","authenticated-orcid":false,"given":"Rirong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9088-8781","authenticated-orcid":false,"given":"Shenghong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.intimp.2024.112506_b0005","doi-asserted-by":"crossref","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG clinical guideline: ulcerative colitis in adults","volume":"114","author":"Rubin","year":"2019","journal-title":"Am. J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112506_b0010","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41572-020-0205-x","article-title":"Ulcerative colitis","volume":"6","author":"Kobayashi","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"5","key":"10.1016\/j.intimp.2024.112506_b0015","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.intimp.2024.112506_b0020","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1093\/ibd\/izz081","article-title":"US practice patterns and impact of monitoring for mucosal inflammation after biologic initiation in inflammatory bowel disease","volume":"25","author":"Limketkai","year":"2019","journal-title":"Inflamm. Bowel Dis."},{"issue":"8","key":"10.1016\/j.intimp.2024.112506_b0025","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1007\/s10620-020-06568-w","article-title":"Understanding determinants of patient preferences between stool tests and colonoscopy for the assessment of disease activity in inflammatory bowel disease","volume":"66","author":"Barsky","year":"2021","journal-title":"Dig. Dis. Sci."},{"issue":"5","key":"10.1016\/j.intimp.2024.112506_b0030","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1002\/med.21893","article-title":"Inflammatory bowel disease biomarkers","volume":"42","author":"Liu","year":"2022","journal-title":"Med. Res. Rev."},{"issue":"5","key":"10.1016\/j.intimp.2024.112506_b0035","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/jgh3.12068","article-title":"Fecal calprotectin correlates with active colonic inflammatory bowel disease but not with small intestinal Crohn's disease activity","volume":"2","author":"Zittan","year":"2018","journal-title":"JGH Open."},{"issue":"10","key":"10.1016\/j.intimp.2024.112506_b0040","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/ibd.20490","article-title":"Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease","volume":"14","author":"Sipponen","year":"2008","journal-title":"Inflamm. Bowel Dis."},{"issue":"3","key":"10.1016\/j.intimp.2024.112506_b0045","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1136\/gut.2004.043406","article-title":"Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease","volume":"54","author":"Costa","year":"2005","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.intimp.2024.112506_b0050","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1053\/j.gastro.2015.07.003","article-title":"Biomarkers of inflammation in inflammatory bowel disease","volume":"149","author":"Sands","year":"2015","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.intimp.2024.112506_b0055","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1053\/j.gastro.2022.12.007","article-title":"AGA clinical practice guideline on the role of biomarkers for the management of ulcerative colitis","volume":"164","author":"Singh","year":"2023","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.intimp.2024.112506_b0060","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1186\/s12876-023-02968-0","article-title":"Combined use of CDAI and blood indices for assessing endoscopic activity in ileocolic Crohn's disease","volume":"23","author":"Hu","year":"2023","journal-title":"BMC Gastroenterol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112506_b0065","doi-asserted-by":"crossref","first-page":"33","DOI":"10.5455\/msm.2022.33.33-36","article-title":"Neutrophil to lymphocyte ratio and platelet to lymphocyte percentage ratio as predictors of in-hospital mortality in sepsis an observational cohort study","volume":"34","author":"Karamouzos","year":"2022","journal-title":"Mater. Sociomed."},{"key":"10.1016\/j.intimp.2024.112506_b0070","doi-asserted-by":"crossref","DOI":"10.1177\/1756284820979442","article-title":"Platelet-to-lymphocyte percentage ratio index: a simple non-invasive index to monitor the endoscopic activity in Crohn's disease","volume":"13","author":"Chen","year":"2020","journal-title":"Therap. Adv. Gastroenterol."},{"issue":"23","key":"10.1016\/j.intimp.2024.112506_b0075","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.intimp.2024.112506_b0080","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1053\/j.gastro.2013.06.010","article-title":"Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"issue":"13","key":"10.1016\/j.intimp.2024.112506_b0085","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.intimp.2024.112506_b0090","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12974-021-02090-6","article-title":"The association of neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, and lymphocyte to monocyte ratio with post-thrombolysis early neurological outcomes in patients with acute ischemic stroke","volume":"18","author":"Gong","year":"2021","journal-title":"J. Neuroinflammation."},{"issue":"4","key":"10.1016\/j.intimp.2024.112506_b0095","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/ibd\/izab099","article-title":"Multiple switches from the originator infliximab to biosimilars is effective and safe in inflammatory bowel disease: a prospective multicenter cohort study","volume":"28","author":"Hanzel","year":"2022","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.intimp.2024.112506_b0100","article-title":"Rapidly achieving clinical remission in ulcerative colitis indicates better endoscopic and histological outcomes. United European","author":"Chen","year":"2023","journal-title":"Gastroenterol. J."},{"key":"10.1016\/j.intimp.2024.112506_b0105","article-title":"Higher serum infliximab concentrations following subcutaneous dosing are associated with deep remission in patients with inflammatory bowel disease","author":"Roblin","year":"2023","journal-title":"J. Crohns Colitis"},{"issue":"5","key":"10.1016\/j.intimp.2024.112506_b0110","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/j.1572-0241.2004.04129.x","article-title":"Platelets in inflammatory bowel disease: clinical, pathogenic, and therapeutic implications","volume":"99","author":"Danese","year":"2004","journal-title":"Am. J. Gastroenterol."},{"issue":"3","key":"10.1016\/j.intimp.2024.112506_b0115","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.pharmthera.2012.10.008","article-title":"Immune aspects of the pathogenesis of inflammatory bowel disease","volume":"137","author":"Hisamatsu","year":"2013","journal-title":"Pharmacol. Ther."},{"issue":"10","key":"10.1016\/j.intimp.2024.112506_b0120","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1093\/ibd\/izaa062","article-title":"Novel prognostic biomarkers of mucosal healing in ulcerative colitis patients treated with Anti-TNF: neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio","volume":"26","author":"Bertani","year":"2020","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.intimp.2024.112506_b0125","doi-asserted-by":"crossref","DOI":"10.1007\/s00431-023-05110-0","article-title":"The role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in the diagnosis and severity of inflammatory bowel disease in children","author":"Zahmatkesh","year":"2023","journal-title":"Eur. J. Pediatr."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924010270?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924010270?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T15:37:48Z","timestamp":1720280268000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924010270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":25,"alternative-id":["S1567576924010270"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112506","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Platelet-to-lymphocyte percentage ratio for assessing disease activity and predicting therapeutic outcomes in ulcerative colitis","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112506","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"112506"}}